Nautilus Biotechnology (NASDAQ:NAUT) Earns Sell (D-) Rating from Weiss Ratings

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Nautilus Biotechnology to a "sell" rating in a research note on Saturday. Two investment analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, Nautilus Biotechnology has an average rating of "Sell" and an average target price of $2.13.

Nautilus Biotechnology Stock Down 15.9%

Shares of NASDAQ NAUT opened at $1.22 on Friday. Nautilus Biotechnology has a 52-week low of $0.62 and a 52-week high of $2.92. The business's 50 day moving average is $0.83 and its two-hundred day moving average is $0.78. The firm has a market cap of $154.10 million, a price-to-earnings ratio of -2.35 and a beta of 1.48.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. Analysts anticipate that Nautilus Biotechnology will post -0.57 EPS for the current fiscal year.

Insider Buying and Selling at Nautilus Biotechnology

In other news, CEO Sujal M. Patel purchased 116,500 shares of the company's stock in a transaction that occurred on Friday, September 5th. The shares were purchased at an average price of $0.67 per share, with a total value of $78,055.00. Following the purchase, the chief executive officer directly owned 10,258,221 shares of the company's stock, valued at approximately $6,873,008.07. This represents a 1.15% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have acquired 220,000 shares of company stock worth $147,635. Insiders own 41.10% of the company's stock.

Institutional Investors Weigh In On Nautilus Biotechnology

Large investors have recently made changes to their positions in the company. Clarius Group LLC lifted its holdings in Nautilus Biotechnology by 14.1% during the 3rd quarter. Clarius Group LLC now owns 1,209,646 shares of the company's stock valued at $1,022,000 after purchasing an additional 149,186 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of Nautilus Biotechnology by 860.0% during the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company's stock worth $316,000 after buying an additional 390,000 shares during the period. Jane Street Group LLC grew its position in shares of Nautilus Biotechnology by 304.1% during the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company's stock worth $210,000 after buying an additional 218,512 shares during the period. Sentinel Trust Co. LBA grew its position in shares of Nautilus Biotechnology by 9.8% during the 1st quarter. Sentinel Trust Co. LBA now owns 280,000 shares of the company's stock worth $241,000 after buying an additional 25,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in Nautilus Biotechnology during the 1st quarter worth approximately $194,000. Institutional investors and hedge funds own 50.71% of the company's stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.